FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20200813E00356
1. Date of relevant event: 10/08/2020
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 01672
4. Name of listed corporation: Ascletis Pharma Inc. - B 
5. Class of shares: Ordinary Shares 
6. Number of issued shares in class: 1,106,336,000
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) WU
(Other names) Jinzi Jason
10. Name of director (Chinese): 吳勁梓 
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1316There has been a change in nature of your interest in the shares because:
any other event (you must briefly describe the relevant event in the Supplementary Information box)
 
2202Interest of your spouse
 
2201Interest of corporation controlled by you
 
44,827,414         
 
Short position 
 
 
 
           
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position599,532,07854.19
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position599,532,07854.19
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2201Interest of corporation controlled by you
Long position597,221,078
2103Interests held jointly with another person
Long position2,311,000
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
           
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
SpouseJudy Hejingdao WU
Long position44,827,414
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
JJW12 LimitedVistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin IslandsJinzi Jason WU100.00Y
Long position552,393,664
Lakemont Holding LLCThe Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Delaware, United StatesJinzi Jason WU43.45Y
Long position44,827,414
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
Judy Hejingdao WUAddresses of individuals are not displayed.
Long position2,311,000
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
Lakemont Remainder TrustAddresses of individuals are not displayed.
5103Founder of a discretionary trust who can influence how the trustee exercises his discretion
Long position44,827,414
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: For Boxes 24, 30 and 32, on July 14, 2020, Lakemont 2018 GRAT ("GRAT") entered into an agreement with Jinzi Jason WU ("Dr. Wu"), pursuant to which GRAT transferred 29.92% interest in Lakemont Holding LLC ("Lakemont") to Dr. Wu. Such interest transfer was completed on August 10, 2020. Upon completion of the transfer, GRAT and Dr. Wu holds 56.55% and 43.45% of Lakemont, respectively. The remaining interest held by GRAT has been transferred to Lakemont Remainder Trust.
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 13/08/2020
(dd/mm/yyyy)